HCW Biologics Inc. (NASDAQ:HCWB) Stock Short Interest Report for October

Posted by on Nov 3rd, 2026

HCW Biologics Inc. (NASDAQ:HCWB – Get Free Report) was the target of a significant drop in short interest in the month of October. As of October 15th, there was short interest totaling 37,709 shares, a drop of 38.1% from the September 30th total of 60,941 shares. Approximately 1.9% of the shares of the stock are sold short. Based on an average trading volume of 226,124 shares, the days-to-cover ratio is currently 0.2 days.

HCW Biologics Stock Up 2.6%

HCW Biologics stock traded up $0.03 during midday trading on Tuesday, reaching $1.15. 5,613 shares of the stock traded hands, compared to its average volume of 1,161,037. The stock has a market cap of $2.57 million, a P/E ratio of -0.04 and a beta of 2.41. The stock’s fifty day moving average is $1.90 and its 200-day moving average is $4.13. HCW Biologics has a 12 month low of $1.09 and a 12 month high of $23.94.

HCW Biologics (NASDAQ:HCWB – Get Free Report) last released its quarterly earnings data on Friday, August 14th. The company reported ($11.58) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.98) by ($9.60). The firm had revenue of $0.14 million during the quarter, compared to the consensus estimate of $0.14 million. HCW Biologics had a negative return on equity of 262.33% and a negative net margin of 83.03%.

Wall Street Analysts Forecast Growth

HCWB has been the subject of a number of recent analyst reports. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of HCW Biologics in a research note on Thursday, October 15th. Wall Street Zen raised HCW Biologics from a “sell” rating to a “hold” rating in a research note on Saturday. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, HCW Biologics has an average rating of “Hold” and an average price target of $30.00.

Check Out Our Latest Research Report on HCW Biologics

About HCW Biologics

(Get Free Report)

HCW Biologics Inc (NASDAQ: HCWB) is a clinical-stage biotechnology company focused on developing immunotherapies for diseases associated with chronic inflammation, immune dysfunction and aging. The company’s research is intended to address conditions in which persistent inflammation contributes to disease progression.

HCW Biologics uses its proprietary TOBI platform to design multifunctional fusion proteins that can target inflammatory pathways and modify immune responses. Its development programs have included HCW9218, an investigational immunotherapy designed to combine immune-stimulating activity with inhibition of transforming growth factor beta, a signaling pathway associated with immune suppression and disease progression.

Featured Stories

Receive News & Ratings for HCW Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HCW Biologics and related companies with MarketBeat.com's FREE daily email newsletter.